These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 38040417)

  • 21. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.
    Cao D; Chen D; Xia JN; Wang WY; Zhu GY; Chen LW; Zhang C; Tan B; Li H; Li YW
    Biomed Pharmacother; 2022 Nov; 155():113705. PubMed ID: 36271541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
    Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
    Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 24. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
    Hong W; Xue M; Jiang J; Zhang Y; Gao X
    J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOXM1 Inhibition Enhances the Therapeutic Outcome of Lung Cancer Immunotherapy by Modulating PD-L1 Expression and Cell Proliferation.
    Madhi H; Lee JS; Choi YE; Li Y; Kim MH; Choi Y; Goh SH
    Adv Sci (Weinh); 2022 Oct; 9(29):e2202702. PubMed ID: 35975458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma.
    Qu T; Zhang W; Yan C; Ren D; Wang Y; Guo Y; Guo Q; Wang J; Liu L; Han L; Li L; Huang Q; Cao L; Ye Z; Zhang B; Zhao Q; Cao W
    J Transl Med; 2023 May; 21(1):341. PubMed ID: 37217923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Decreased Expression of Programmed Death Ligand-L1 by Seven in Absentia Homolog 2 in Cholangiocarcinoma Enhances T-Cell-Mediated Antitumor Activity.
    Zheng H; Zheng WJ; Wang ZG; Tao YP; Huang ZP; Yang L; Ouyang L; Duan ZQ; Zhang YN; Chen BN; Xiang DM; Jin G; Fang L; Zhou F; Liang B
    Front Immunol; 2022; 13():845193. PubMed ID: 35154166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis.
    Huang Y; Xia L; Tan X; Zhang J; Zeng W; Tan B; Yu X; Fang W; Yang Z
    Cell Mol Biol Lett; 2022 Jun; 27(1):43. PubMed ID: 35658874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
    Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
    Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. METTL14 regulates CD8
    Sun C; Wang J; Li H; Liu L; Lin Y; Zhang L; Zu X; Zhu Y; Shu Y; Shen D; Wang Q; Liu Y
    World J Surg Oncol; 2024 May; 22(1):128. PubMed ID: 38725005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precisely Targeted Nano-Controller of PD-L1 Level for Non-Small Cell Lung Cancer Spinal Metastasis Immunotherapy.
    Zhou L; Liang H; Ge Y; Ding W; Chen Q; Zhang T; Xiao L; Li Y; Dong J; He X; Xue F; Jiang L
    Adv Healthc Mater; 2022 Oct; 11(20):e2200938. PubMed ID: 35904523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.